Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
SAB-185
SAB Biotherapeutics
COVID-19
2 trials -
SAB-301
SAB Biotherapeutics
Middle East Respiratory Syndrome Coronavirus
1 trial -
SAR441000
Atrium Therapeutics
Metastatic Neoplasm
1 trial -
SB-728-T
SANGAMO THERAPEUTICS, INC
HIV Infection
1 trial -
SB-728mR-HSPC Infusion 3 days following busulfan conditioning
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
SB-FIX
SANGAMO THERAPEUTICS, INC
Hemophilia B
1 trial -
SC HYLENEX and Ceftriaxone
HALOZYME THERAPEUTICS, INC.
Healthy
1 trial -
SER-214
Serina Therapeutics
Parkinson's Disease
1 trial -
SER-252 (PEOZ-apomorphine)
Serina Therapeutics
PARKINSON DISEASE (Disorder)
1 trial -
SER-262
Seres Therapeutics
Clostridium Difficile Infection
1 trial -
SER-287
Seres Therapeutics
Ulcerative Colitis
1 trial -
SHP465 12.5mg
Takeda
Attention Deficit Hyperactivity Disorder (ADHD)
1 trial -
SION-451
Sionna Therapeutics
Cystic Fibrosis (CF)
1 trial -
SKY0402
Pacira Ireland Limited
Postoperative Pain Management
1 trial -
SLN124
Silence Therapeutics plc
Healthy Volunteers
1 trial -
SLN124
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia
1 trial -
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia
1 trial -
SLN360
Silence Therapeutics plc
Hyperlipidemias
1 trial -
SMT C1100
Summit Therapeutics
Muscular Dystrophy, Duchenne
1 trial -
SMT C1100
Summit Therapeutics
Duchenne Muscular Dystrophy
1 trial -
SOC + TSC-100
TScan Therapeutics
AML
1 trial -
SOM 230 / Pasireotide
United Therapeutics Europe Ltd
Atypical Ductal Breast Hyperplasia
1 trial -
SPARC1210
Advanced Accelerator Applications
Breast Cancer
1 trial -
SPARC1613
Advanced Accelerator Applications
Recurrent or Metastatic Breast Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources